文献速递心外重症与机械循环支持

凝血因子XII促进静脉-动脉体外膜氧合大鼠模型中的血栓炎症反应

Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-09-07

研究利用CRISPR/Cas9构建的凝血因子XII缺陷(FXII-/-)Sprague-Dawley大鼠,在微创静脉-动脉体外膜氧合(VA ECMO)模型中比较野生型与FXII-/-大鼠的血栓炎症反应。结果发现无抗凝时FXII-/-大鼠可维持ECMO 1小时,而野生型大鼠在10分钟内发生血栓性回路故障;FXII缺陷还显著减轻ECMO诱导的肝脏中性粒细胞迁移、高分子量激肽原裂解和补体激活。结论提示FXII启动ECMO中的止血系统激活和关键炎症后遗症,靶向FXII的治疗可能限制血栓栓塞和不良炎症并发症。

要点

  • 无药物抗凝时,FXII-/-大鼠维持VA ECMO 1小时,野生型大鼠10分钟内发生血栓性回路故障。
  • 阿加曲班抗凝可使野生型和FXII-/-大鼠均维持ECMO 1小时而无血栓并发症。
  • ECMO导致肝脏中性粒细胞迁移增加、高分子量激肽原裂解和补体激活,FXII基因缺失可减弱或消除这些反应。

核心结论

  • FXII启动ECMO中的止血系统激活和关键炎症后遗症,提示靶向FXII的治疗可能限制该场景下的血栓栓塞和不良炎症并发症。

研究设计与样本

  • 使用CRISPR/Cas9构建FXII缺陷(FXII-/-)Sprague-Dawley大鼠,在微创静脉-动脉(VA)ECMO模型中比较野生型(WT)与FXII-/-大鼠。
  • 实验分2个队列:无药物抗凝的ECMO大鼠和接受阿加曲班抗凝的ECMO大鼠;大鼠维持ECMO 1小时或直至回路故障。
  • 比较对象还包括未受攻击的大鼠和接受无ECMO假手术的大鼠。

主要发现

  • 无药物抗凝时,FXII-/-大鼠在整个1小时实验中以低阻力维持ECMO;而野生型大鼠在10分钟内发生血栓性回路故障。
  • 阿加曲班使野生型和FXII-/-大鼠均能维持ECMO 1小时而无血栓并发症。
  • ECMO导致肝脏中性粒细胞迁移增加,FXII缺陷显著减弱该增加。
  • ECMO导致高分子量激肽原裂解和补体激活增加,FXII基因缺失可消除这些变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Factor XII (FXII) is a multifunctional protease capable of activating thrombotic and inflammatory pathways. FXII has been linked to thrombosis in extracorporeal membrane oxygenation (ECMO), but the role of FXII in ECMO-induced inflammatory complications has not been studied. We used novel gene-targeted FXII- deficient rats to evaluate the role of FXII in ECMO-induced thromboinflammation. METHODS: FXII-deficient (FXII-/-) Sprague-Dawley rats were generated using CRISPR/Cas9. A minimally invasive venoarterial (VA) ECMO model was used to compare wild-type (WT) and FXII-/- rats in 2 separate experimental cohorts: rats placed on ECMO without pharmacologic anticoagulation and rats anticoagulated with argatroban. Rats were maintained on ECMO for 1 hour or until circuit failure occurred. Comparisons were made with unchallenged rats and rats that underwent a sham surgical procedure without ECMO. RESULTS: FXII-/- rats were maintained on ECMO without pharmacologic anticoagulation with low resistance throughout the 1-hour experiment. In contrast, WT rats placed on ECMO without anticoagulation developed thrombotic circuit failure within 10 minutes. Argatroban provided a means to maintain WT and FXII-/- rats on ECMO for the 1-hour time frame without thrombotic complications. Analyses of these rats demonstrated that ECMO resulted in increased neutrophil migration into the liver that was significantly blunted by FXII deficiency. ECMO also resulted in increases in high molecular weight kininogen cleavage and complement activation that were abrogated by genetic deletion of FXII. CONCLUSIONS: FXII initiates hemostatic system activation and key inflammatory sequelae in ECMO, suggesting that therapies targeting FXII could limit both thromboembolism and inopportune inflammatory complications in this setting.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kharnaf M, Zafar F, Hogue S, et al. Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2023. PMID: 37683721. doi:10.1016/j.jtcvs.2023.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。